title: Antipsychotics in pregnancy.
abstract: Women who are pregnant and who have a history of psychosis are commonly managed with antipsychotic medications. The evidence regarding the use of antipsychotics in pregnancy has been insufficient to provide adequate support for this practice and is a concern for clinicians and women alike. This review presents literature surrounding the use of antipsychotic medications in pregnancy, providing an overview of the historical and contemporary perspectives which influence clinicians prescribing practices. Data were sourced from Medline, CINAHL, PsycINFo, using the terms antipsychotics with pregnancy and psychosis or schizophrenia. This was expanded to include the most common atypical antipsychotics: olanzapine, risperidone, clozapine, quetiapine, ziprasidone and aripiprazole. Literature was found reporting the use of antipsychotic medications in pregnancy since the introduction of antipsychotics in the 1950s, comprising mainly of authors' reviews of the literature, case studies, retrospective reports, drug company registries and more recently a prospective comparative study. This review identifies that the literature provides no clear answer for clinicians as to the risk associated with the use of antipsychotics in pregnancy. To this effect, recently in Australia, the National Register of Antipsychotic Medications in Pregnancy was established to prospectively collect information regarding outcomes for mother and baby, when antipsychotic medications have been used during pregnancy.
authors.affiliation: Senior Lecturer - Midwifery and Mental Health Nursing, School of Nursing and Midwifery, Monash University.
authors.forename: K
authors.initials: K
authors.lastname: McCauley-Elsom
authors.forename: C
authors.initials: C
authors.lastname: Gurvich
authors.forename: S J
authors.initials: SJ
authors.lastname: Elsom
authors.forename: J
authors.initials: J
authors.lastname: Kulkarni
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D014150:Antipsychotic Agents / Q000627:therapeutic use / Q000633:toxicity*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use / Q000633:toxicity; D003024:Clozapine / Q000627:therapeutic use / Q000633:toxicity; D016640:Diabetes, Gestational / Q000139:chemically induced / Q000451:nursing; D003987:Dibenzothiazepines / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000451:nursing*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000451:nursing*; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000627:therapeutic use / Q000633:toxicity; D018967:Risperidone / Q000627:therapeutic use / Q000633:toxicity; D013844:Thiazoles / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D000068180:Aripiprazole; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine